APEN
$8.26
Apollo Endosurgery
($.14)
(1.67%)
APEN
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.20)
Revenue:  $16.60 Mil
Monday
Jan 31
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when APEN reports earnings?
Beat
Meet
Miss

Where is APEN's stock price going from here?
Up
Flat
Down
Stock chart of APEN
Analysts
Summary of analysts' recommendations for APEN
Score
Grade
Pivots
Resistance
$9.14
$8.78
$8.52

$8.16

Support
$7.90
$7.54
$7.28
Tweet
Growth
Description
Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas.